Patient selection
leptomeningeal disease, malignancy, HIV, hepatitis B surface antigen or, heart failure, hepatitis
MYOCARDIAL INFARCTION, DISEASE, SOLID TUMOR, ONCOLOGY, HEART FAILURE, HEPATITIS
The trial population included patients with a histologic or cytologic diagnosis of an advanced solid tumor without a curative or standard chemotherapy treatment option. Patients had to be ≥ 18 years of age, have an Eastern Cooperative Oncology Group performance status ≤ 2 and have a life expectancy ≥ 12 weeks. Eligibility required adequate hepatic, renal, and bone marrow function and a washout period of at least 4 weeks (6 weeks for mitoxantrone or mitomycin therapy). Patients were excluded if they had uncontrolled central nervous system (CNS) disease, a primary CNS malignancy, leptomeningeal disease, symptomatic heart failure, myocardial infarction within the prior 6 months, or a positive test for HIV, hepatitis B surface antigen or hepatitis C.